Cell line · CVCL_4358
Papers135
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 135
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PubMed 42999416 | Transl Lung Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrated Computational Pipeline Combining Metabolomics and Network Pharmacology for Bioactive Scaffold Discovery: Application to Antarctic Moss Chorisodontium aciphyllum. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Blocking aryl hydrocarbon receptor remodels myeloid-T cell crosstalk and enhances anti-PD-1 response in the tumor microenvironment. | Exp Hematol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combined HER2-targeted mRNA-LNP vaccine and radiotherapy suppress Lewis lung carcinoma growth in mice: Efficacy and mechanistic insights. | Bioeng Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NAPRT loss promotes lung tumor initiation and growth through AKT signaling independently of NAD+ biosynthesis. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Intravenously deliverable oncolytic virus VET3-TGI favorably alters the tumor microenvironment. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Collagen-Binding IL-15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self-Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HIF1A+CSF3R+ neutrophils-dominated hypoxic niche induced metabolic reprogramming for neoadjuvant therapy resistance in NSCLC. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment. | J Exp Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Surface display of co-stimulatory ligand B7H2 on engineered bacteria enhances tumor immunotherapy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Acetoacetate-GPR43 axis epigenetically silences IL-6/CSF1 to restrict TAMs-driven metastatic lung cancer. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of NCCRP1 overcomes immune evasion in lung adenocarcinoma. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LPL-Positive Endothelial Cells Control T-cell Homing in Liver Metastasis. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of XNW5004 as a novel EZH2 inhibitor that enhances anti-tumor immunity and synergizes with PD-1 blockade immunotherapy in lung adenocarcinoma. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Coordinated Immune Activation Following KRAS Inhibition in Syngeneic Models Reveals Molecular Pathways that Potentiate and Limit Antitumor Immunity. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An inflammation-modulating ferroptotic nanoplatform for immune-compatible cancer therapy. | J Nanobiotechnology | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_4358/papers